A large number of clinical trials have shown stem cell therapy to be a promising therapeutic
approach for the treatment of cardiovascular diseases. Since the first transplantation into …

Given the rising prevalence of cardiovascular disease worldwide and the limited therapeutic
options for severe heart failure, novel technologies that harness the regenerative capacity of …

Some of the most significant leaps in the history of modern civilization—the development of
article in China, the steam engine, which led to the European industrial revolution, and the …

Rationale: Autologous bone marrow mesenchymal stem cells (MSCs) and c-kit+ cardiac
progenitor cells (CPCs) are 2 promising cell types being evaluated for patients with heart …

Myocardial infarction is a leading cause of morbidity and mortality worldwide. Although
medical and surgical treatments can significantly improve patient outcomes, no treatment …

Ischemic heart diseases (IHDs) remain major public health problems with high rates of
morbidity and mortality worldwide. Despite significant advances, current therapeutic …

Over the past two decades cardiac cell therapy (CCT) has emerged as a promising new
strategy to cure heart diseases at high unmet need. Thousands of patients have entered …

Rationale: The TIME trial (Timing in Myocardial Infarction Evaluation) was the first cell
therapy trial sufficiently powered to determine if timing of cell delivery after ST-segment …

The last decade has witnessed the publication of a number of stem cell clinical trials,
primarily using bone marrow‐derived cells as the injected cell. Much has been learned …

Advances in early reperfusion therapies focused on the revascularization of the ischemic
tissues, in the last decades, lead to reduced mortality in acute myocardial infarction (MI) …